Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease.

ABSTRACT:

Aims

Metformin is first-line treatment of type 2 diabetes mellitus and reduces cardiovascular events in patients with insulin resistance and type 2 diabetes. Target tissue for metformin action is thought to be the liver, where metformin distribution depends on facilitated transport by polyspecific transmembrane organic cation transporters (OCTs). Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the western world with strong associations to insulin resistance and the metabolic syndrome, but whether NAFLD affects metformin biodistribution to the liver is not known. In this study, the primary aim was to investigate in vivo hepatic uptake of metformin dynamically in humans with variable degrees of liver affection. As a secondary aim, we wished to correlate

SUBMITTER: Sundelin EIO 

PROVIDER: S-EPMC6624391 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature